Beam Therapeutics dosed the first patient in the global pivotal cohort of its BEAM-302 trial for AATD and reported $1.2 billion in cash, indicating continued clinical progress and operational strength.
Beam Therapeutics dosed the first patient in the global pivotal cohort of its BEAM-302 trial for AATD and reported $1.2 billion in cash, indicating continued clinical progress and operational strength.